AI In Genomics Market growing at a CAGR of 40.30% from 2026 to 2033

Key Market Trends & Insights

• North America AI in genomics market held the largest share of over 38.36% of the global market in 2025.
• The AI in genomics industry in the U.S. is expected to grow significantly over the forecast period.
• Based on component, the software segment held the largest market share of 41% in 2025.
• Based on technology, the machine learning segment held the largest market share in 2025.
• Based on functionality, the genome sequencing segment held the highest market share in 2025.
• Based on application, the drug discovery & development segment held the highest market share of 33.57% in 2025.
• Based on end use, the pharmaceutical and biotechnology companies segment held the largest market share of 37.39% in 2025.

Market Size & Forecast

• 2025 Market Size: USD 1.26 Billion
• 2033 Projected Market Size: USD 18.82 Billion
• CAGR (2026-2033): 40.30%
• North America: Largest market in 2025
• Asia Pacific: Fastest growing market

Request Free Sample Report: https://www.grandviewresearch.com/industry-analysis/ai-genomics-market-report/request/rs1

Moreover, technological advancements and industry partnerships are strengthening the market environment. Rapid advances in next-generation sequencing have significantly increased the volume and complexity of genomic datasets. Whole-genome and multi-omics studies generate data that exceed the capacity of traditional bioinformatics tools. For instance, the National Human Genome Research Institute predicts that genomics research is expected to generate between 2 and 40 exabytes of data within the next decade. However, AI enables scalable processing, interpretation, and integration of these large datasets. The growing intensity of data makes AI essential for genomic research and clinical applications. This structural shift strongly drives AI adoption in genomics.

Moreover, the increasing demand for precision medicine further drives market growth. Genomic insights are crucial for identifying patient-specific disease risks and predicting therapy responses. AI supports the interpretation of complex genotype-phenotype relationships at scale. Precision oncology, rare disease diagnostics, and pharmacogenomics increasingly rely on AI-enabled genomics. In addition, integration with clinical data improves actionable decision-making. For instance, in November 2025, Complete Genomics and SOPHiA GENETICS collaborated at the AMP Annual Meeting to integrate IMSK-IMPACT and MSK-ACCESS, powered by SOPHiA DDM, onto the DNBSEQ-T1+ sequencer, delivering end-to-end, AI-driven cancer genomic profiling.

Market Concentration & Characteristics

The chart below illustrates the relationship between industry concentration, industry characteristics, and industry participants. The x-axis represents the level of industry concentration, ranging from low to high. The y-axis represents various industry characteristics, including industry competition, level of partnerships & collaboration activities, degree of innovation, impact of regulations, and regional expansion. The AI in genomics market is fragmented, with several emerging players entering the market. The degree of innovation is high. The level of merger & acquisition activities is moderate. Moreover, the impact of regulations and the regional expansion of industry is high.

AI in genomics market is characterized by constant innovation, with a strong focus on launching new platforms and devices to enhance drug discovery and disease diagnostics. For instance, in September 2025, Cytiva and Paris-based WhiteLab Genomics partnered to utilize WhiteLab’s AI platform to optimize stable cell line development for AAV-based genomic medicines through in silico clone selection.

Component Insights

Based on components, the software segment held the largest market share of 41.00% in 2025. In addition, this segment is expected to witness the fastest CAGR during the forecast period. The rapid adoption of AI-based software solutions for genomics by healthcare institutions, research and development centers, and pharmaceutical and biotechnology companies are expected to drive the segments. Moreover, increasing use of genomics in precision medicine drives segment growth further. For instance, in June 2023, Illumina launched PrimateAI-3D, an AI algorithm predicting disease-causing genetic mutations with enhanced accuracy.

The hardware segment is anticipated to grow significantly over the forecast period. This segment comprises high-throughput sequencing systems, automated sample preparation platforms, data storage infrastructure, and specialized computing hardware optimized for genomic analytics. Advances in next-generation sequencing and long-read technologies generate large-scale genomic datasets that necessitate robust AI-ready hardware. Integration of GPUs, TPUs, and high-performance servers enables accelerated sequence alignment, variant calling, and genome assembly.

Application Insights

Based on application, the drug discovery & development segment accounted for the largest revenue share of 33.57% in 2025. AI algorithms analyze genetic variants, gene expression profiles, and pathway interactions to discover disease-driving mechanisms. As a result, these insights improve target selection and reduce attrition in early-stage drug development. Moreover, integration of genomics with AI enables patient stratification and biomarker discovery, further enhancing the drug development process. Furthermore, this segment supports precision therapeutics by aligning drugs with genetic profiles. This approach enhances efficiency across preclinical pipelines.

The precision medicine segment is anticipated to witness the fastest growth of over 46% during the forecast period. Growth in this segment is driven by the expansion of genomic testing and an increasing demand for individualized therapies. The integration of AI enhances the interpretation of complex genomic data in clinical settings. Precision medicine applications are prominent in oncology, rare diseases, and pharmacogenomics.

End Use Insights

Based on end use, the pharmaceutical and biotechnology companies’ segment held the largest market share of 37.39%. These organizations leverage AI-driven genomic analytics to improve target identification, biomarker discovery, and patient stratification. Integration of genomics with AI reduces drug development timelines and attrition rates. Moreover, AI tools also enable drug repurposing and lifecycle management. For instance, in October 2025, Genomics, a techbio company, launched Mystra, an AI-enabled human genetics platform built on the world’s largest, harmonized genotype-phenotype database and 20,000+ GWAS, to supercharge target discovery.

AI In Genomics Market Report Scope

Report Attribute	Details
Market size value in 2026	USD 1.76 billion
Revenue forecast in 2033	USD 18.82 billion
Growth rate	CAGR of 40.30% from 2026 to 2033
Actual data	2021 – 2025
Forecast period	2026 – 2033
Quantitative units	Revenue in USD million and CAGR from 2026 to 2033
Report coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered	Component, technology, functionality, application, end use, region
Regional scope	North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country scope	U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key companies profiled	Microsoft Corporation; NVIDIA Corporation; DEEP GENOMICS; Data4Cure, Inc.; Freenome Holdings, Inc.; Thermo Fisher Scientific; Illumina, Inc.; SOPHiA GENETICS; BenevolentAI; Fabric Genomics
Customization scope	Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options